NasdaqGS - Delayed Quote USD

Metagenomi, Inc. (MGX)

1.4300
-0.0200
(-1.38%)
At close: June 13 at 4:00:01 PM EDT
1.4000
-0.03
(-2.10%)
After hours: June 13 at 6:56:29 PM EDT
Loading Chart for MGX
  • Previous Close 1.4500
  • Open 1.4200
  • Bid 1.3900 x 100
  • Ask 1.4700 x 100
  • Day's Range 1.3900 - 1.4800
  • 52 Week Range 1.2300 - 5.6290
  • Volume 581,585
  • Avg. Volume 392,460
  • Market Cap (intraday) 53.456M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1.8500
  • Earnings Date Aug 13, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 12.80

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer. Metagenomi, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.

metagenomi.co

176

Full Time Employees

December 31

Fiscal Year Ends

Recent News: MGX

View More

Performance Overview: MGX

Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MGX
60.39%
S&P 500 (^GSPC)
1.62%

1-Year Return

MGX
76.17%
S&P 500 (^GSPC)
10.00%

3-Year Return

MGX
86.05%
S&P 500 (^GSPC)
59.40%

5-Year Return

MGX
86.05%
S&P 500 (^GSPC)
96.53%

Compare To: MGX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: MGX

View More

Valuation Measures

Annual
As of 6/13/2025
  • Market Cap

    53.46M

  • Enterprise Value

    -128.08M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.17

  • Price/Book (mrq)

    0.25

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -172.21%

  • Return on Assets (ttm)

    -15.37%

  • Return on Equity (ttm)

    -31.93%

  • Revenue (ttm)

    45.26M

  • Net Income Avi to Common (ttm)

    -77.95M

  • Diluted EPS (ttm)

    -1.8500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    225.97M

  • Total Debt/Equity (mrq)

    20.90%

  • Levered Free Cash Flow (ttm)

    -68.74M

Research Analysis: MGX

View More

Company Insights: MGX

Research Reports: MGX

View More

People Also Watch